IRLAB Therapeutics AB Class A Financial Overview
IRLAB Therapeutics AB Class A's market cap is currently kr164.10M. The company's EPS TTM is kr-0.238; its P/E ratio is -1.24; IRLAB Therapeutics AB Class A is scheduled to report earnings on October 29, 2025, and the estimated EPS forecast is kr―. See an overview of income statement, balance sheet, and cash flow financials.
